Number of shares of stock issued during the period pursuant to acquisitions.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Name:	us-gaap_StockIssuedDuringPeriodSharesAcquisitions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

NON CONTROLLING INTEREST (Details Narrative) - shares	1 Months Ended
NON CONTROLLING INTEREST (Details Narrative) - shares	Mar. 26, 2026	Oct. 31, 2020	Jul. 28, 2016
Joseph DeSanto MD [Member]
Descirption of management services agreement		a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue
BioCorRx Pharmaceuticals, Inc [Member]
Ownership percentage			24.20%
Ownership retained percent			75.80%
BioCorRx Inc. [Member]
Ownership percentage	12.15%
Common stock shares issued in exchange	2,263,371